biofreedom

Biosensors International Group has obtained a conditional investigational device exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate a US-based clinical trial of its BioFreedom polymer-free drug-coated stent (DCS) system.

Featuring a micro-structured abluminal surface, the BioFreedom DCS permits the controlled release of a highly lipophilic anti-restenotic drug, Biolimus A9 (BA9), without the use of a polymer.

The BioFreedom US IDE feasibility trial is designed to collect additional safety and effectiveness data for the BioFreedom system and to support a future pivotal IDE study.

According to the company, this is the first clinical study within the US evaluating polymer-free DCS, and also the first US clinical study of a device benefitting from the use of the Biolimus A9 (BA9) drug.

The multi-centre and prospective trial will enroll around 100 patients at up to five centres. Due to the unique features of BioFreedom, the FDA agreed with a post-implant strategy requiring only three months of dual anti-platelet therapy (DAPT) for this study.

In addition, to establish the product’s safety and efficacy profile, LEADERS FREE, BioFreedom trial is applying a one-month DAPT strategy in patients at high risk of bleeding.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"This is the first clinical study within the US evaluating polymer-free DCS."

The objective of this trial is to confirm that BioFreedom is as safe as a bare-metal stent (BMS) in this patient group, and can deliver the anti-restenotic benefit of a drug-eluting stent (DES), with only a one-month course of DAPT.

BioFreedom demonstrated fruitful 12-month late lumen loss and sustained safety up to four years in its first-in-man (FIM) study. The polymer-free DCS also demonstrated no evidence of definite or probable stent thrombosis.

Biosensors International Group CEO Dr Jack Wang said IDE approval for the BioFreedom US trial represents a major milestone for the company because it is its first US-based clinical study of a stent.

"The US is the largest national market for medical devices," Wang said. "We look forward to introducing our unique and ground-breaking interventional cardiology products there."

Earlier in January 2013, the company obtained CE Mark approval for BioFreedom and is currently available in limited and selected markets.


Image: Biosensors announces IDE approval for BioFreedom US trial. Photo: courtesy of Biosensors International Group, Ltd.